Crossmark

Comment on: “Differences in In Vitro Properties of Pancreatin Preparations for Pancreatic Exocrine Insufficiency as Marketed in Russia and CIS”

Published Online: 2021-10-20

Published Print: 2021-12

Authors

Petersen, Karl-Uwe https://orcid.org/0000-0002-2496-503X
License Information

Text and Data Mining valid from 2021-10-20

Version of Record valid from 2021-10-20
More Information

Article History

Accepted: 20 September 2021

First Online: 20 October 2021

Declarations

:

: The author has not received funding for the preparation of this manuscript.

: In the past 2 years, KUP has received consulting fees from Behring, BioQPharma, Hexal, Luvos, Nordmark, PAION, Ursapharm, and VarmX.

Document is current